Human plasma-derived proteins, such as immunoglobulins, coagulation factors, α1-antitrypsin, fibrin sealAbstract ants, and albumin, are widely used as therapeutics for many serious and life-threatening medical conditions. The human origin of these proteins ensures excellent efficacy and compatibility but may also introduce the risk of unintentional disease transmission. Historically, only viruses, particularly hepatitis and HIV, have posed serious threats to the safety of these therapeutics. Fortunately, between 1970 and 1990, the molecular biology of each of the major viruses was elucidated. These advances led to the development and implementation of effective donor screening tests, mainly based on immunoassays and nucleic acid testing, which resulted in a significant reduction of disease transmission risk. In addition, viral inactivation and removal steps were implemented and validated by manufacturers, further reducing the risk associated with known, as well as unidentified, viruses. Since the late 1990s, a different class of transmissible agent, referred to as prions, has been identified as a new risk for disease transmission. However, prion diseases are very rare, and prion transmission through plasma-derived proteins has not been reported to date. The prion-related risk is minimized by deferring donors with certain key risk factors, and by the manufacturing processes that are capable of removing prions. Advances in science and pathogen safety-related technology, compliance with good manufacturing practices by manufacturers, and increasingly stringent regulatory oversight, has meant that plasma-derived proteins have been developed into today's highly effective therapeutics with very low risk of disease transmission.
In the mid-1940s, the Cohn-Oncley fractionation process was the 1970s, another blood-borne hepatitis virus, which was referred developed to isolate therapeutic proteins from human plasma, to as 'non-A, non-B' hepatitis and later identified as mainly caused based on the solubility differences between individual proteins by the hepatitis C virus (HCV), became more prominent. [8, 9] In under a given solvent condition. [1] Subsequently, techniques such 1982, the first of many HIV infections transmitted by blood as filtration, ultrafiltration, and chromatography have been incorproducts among hemophilic patients was reported.
[10] The awareporated in manufacturing processes to increase the purity and yield ness of potential virus transmission by blood and blood products of products. These advances have led to a continuous supply of prompted active research and development efforts in the field to human plasma-derived proteins that are essential to the treatment reduce, remove, or inactivate these viruses as well as any emerging of many serious medical conditions and diseases, including albuviruses. min for shock and burn treatment, immunoglobulins for immuOne of the risk-reduction measures is the initial questioning to nodeficiencies, coagulation factors for hemophilia, and α 1 -antiidentify and defer disease-carrying or high-risk donors. This is trypsin for hereditary emphysema. Although human plasma-derparticularly important when a disease is associated with a particuived proteins are administered to save millions of lives every year, lar behavior(s) or geographic region(s), or when a disease-specific all biologic products carry the risk of pathogen contamination. diagnostic test is not available. The regulations for donor qualifi- Table I lists some of the pathogens that have been shown to be cation are well established in major industrial countries and are transmissible or have the potential for transmission by blood.
continuously revised to accommodate emerging diseases. The Historically, since large pathogens such as bacteria and parasites source-plasma and therapeutics industry, as represented by the are removed by sterile filtration or destroyed by a freeze-thaw Plasma Protein Therapeutics Association (PPTA), has also implecycle, only viruses have posed serious threats to the safety of mented initiatives to improve the donor selection process. One plasma-derived proteins.
example is the compilation of the National Donor Deferral RegisThe first of many blood-borne viruses to be identified was the try (NDDR), a database of permanently deferred donors in North hepatitis B virus (HBV), [6] whose surface antigen was discovered in the mid-1960s. [7] After the implementation of HBV testing in America, available since December 1993.
Donor selection is only the first layer of defence against the ma. Although whole blood and plasma products are both regulated transmission of diseases. Subsequently, the collected donations are by many of the same agencies worldwide and often by the same tested for major clinically relevant viruses (table I) and positive or policies, there are profound differences in the way whole blood elevated plasma units are removed. In addition, removal and and plasma are collected, stored, and processed. Unlike blood, the inactivation steps are incorporated into manufacturing processes to process of collecting plasma removes cellular components, theretarget pathogens that might have escaped detection or to prevent by reducing the risk for contamination by cell-associated pathotransmission of emerging viruses of unknown nature. Testing, gens. While whole blood cannot be frozen, plasma for fractionaremoval, and inactivation of viruses, and the measures that are tion is stored at sub-freezing temperatures. The long-term storage currently being used to reduce the theoretical risk of prion transof frozen plasma allows the implementation of a holding period mission, are discussed in detail in the following sections.
during which donor qualification is reassessed (commonly referred to as 'donor look-back') and disqualified plasma units are removed. This procedure is very effective in lowering residual risk 1. Detection of Blood-Borne Viral Pathogens that may be associated with early infections during the pre-seroTraditionally, a common perspective has been used to address conversion 'window period', when the markers of infection are pathogen detection issues associated with whole blood and plasundetectable by a specific test. [11] b Associated with cellular fractions, not present in plasma in significant quantity.
c To date, there has been no report of SARS transmission by human blood or blood products.
d Non-enveloped viruses could be inactivated by heat and/or removed by precipitation/nanofiltration.
e Large pathogens could be removed by sterile filtration.
f To date, there has been no report of prion transmission by human plasma products.
g Prions could be removed by precipitation/filtration. Ab = antibody testing; Ag = antigen testing; CJD = Creutzfeldt-Jakob disease; CMV = Cytomegalovirus; ds = double-stranded; EBV = Epstein-Barr virus; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HSV = herpes simplex virus; HTLV = human T-cell lymphotropic virus; NAT = nucleic acid testing; SARS = severe acute respiratory syndrome; ss = single-stranded; vCJD = variant Creutzfeldt-Jakob disease; VSV = vesicular stomatitis virus; WNV = West Nile virus.
The duration of a window period is defined by the performance mates of residual risk among US blood donors (e.g. the probability specifications of the technology used for detection. For serologythat a donor is donating during the pre-seroconversion window) based tests (i.e. tests that detect viral-specific antigens and antibosuggest a dramatic decrease since the introduction of donor HIV dies), a window period could be the result of limited test sensitivity protocols in 1985, [16] from approximately 1 per 50 000 donors to for viral antigens or the result of delayed antibody response in <1 per 500 000 donors. patients. Improvements in existing technologies and the develop- The screening of blood and plasma donors for HCV was (NAT), increase the opportunities to shorten the window period.
implemented in 1990, following the identification of the virus Depending on the targeted viral infection, acute viremia may be responsible for the majority of the cases of non-A, non-B viral assessed by the detection of viral antigens or nucleic acids in hepatitis and the development of analyte-specific reagents based whole blood or plasma samples, whereas resolved infections or on viral antigens. [8, 17] The first-generation test was based on a chronic viremia are more readily indicated by the presence of single peptide, but subsequent improvements were introduced and antibody.
two tests that utilize multiple peptides for antibody capture have been approved. [18] Analyses in which different versions of the test
Detection of Virus-Specific Antibodies
were compared indicate that the incremental modifications have improved assay performance.
[19] The pre-seroconversion window The detection of antibodies in response to viral infection refor HCV is relatively long, averaging approximately 80 days. [20] mains one of the most conventional and widely used approaches to Infected donors are typically unaware of their infections because determine the prevalence of relevant human pathogens within few symptoms are evident during this period despite fluctuating specific populations. The detection of antibodies as a diagnostic viral loads that sometimes exceed 10 8 copies of the viral genome/ indicator remains an important tool, particularly when faced with mL.
[21] These conditions contribute to an elevated residual risk (1 newly emerging pathogens whose characteristics are poorly deper 103 000 US volunteer blood donors) associated with this prefined or unknown. Moreover, the detection of different classes of seroconversion window. [20] virus-specific antibodies offers predictive value in addition to diagnostic value when applied to donor or patient history. Virus-
Detection of Viral Antigens
specific antibody testing remains an important component of current donor screening programs targeting severe human pathoViral antigens are detected early in infection, before the appeargens, such as HIV-1/2 and HCV, which typically establish ance of circulating antibodies. This period frequently overlaps the debilitating chronic infections. Because accuracy in diagnosis of prodrome, and many donors are likely to appear asymptomatic. these types of infections is critical, antibody testing protocols Viral replication can be particularly robust during this period, with typically involve a combination of donor screening and confirmaviral loads typically increasing exponentially during a relatively tory assays.
short period of time. Understandably, this phase of infection may pose the greatest level of risk to both public health and product
Detection of HIV-Specific Antibodies
safety. The direct detection of specific viral antigens provides the Since 1985, several enzyme immunoassay-based methods have opportunity to notify infected donors and to remove potentially been approved as primary donor screening tests for the detection infectious plasma prior to entry into the manufacturing inventory. of HIV-specific antibodies. [12] Three additional test systems, in- The conventional paradigm for the routine detection of active is characterized by an acute primary phase during which patients viremia in human blood and plasma was established approximateexhibit a wide range of flu-like symptoms over a 2-to 3-week ly 30 years ago with the implementation of radioimmune assays period. [13] Seroconversion typically follows this period, marking (RIA) specific for the HBV surface antigen (HBsAg), [22] which the end of the pre-seroconversion window. However, incubation was initially referred to as the Australia (Au) antigen or the times may vary widely, from a few days up to 3 months, and hepatitis-associated antigen. [23, 24] The association of this viral seroconversion may occur between 1 and 10 weeks. [14] A longmarker with the transmission of infectious hepatitis through plasterm asymptomatic phase that is characteristic of latent or lowma-based therapies generated interest in how infectious viral level persistent infection typically follows seroconversion.
[15] Estiparticles partitioned during the plasma fractionation process. The ability to analyze the partitioning of pathogens through the trackindustry and a regulatory goal. The recent licensure of a number of ing of defined markers created new opportunities to design frac-NAT testing systems specific for the detection of HIV-1 RNA has tionation and purification processes with pathogen safety as a provided the opportunity to eliminate p24-antigen testing from the primary consideration. [25, 26] Moreover, the systematic detection of donor HIV screening protocol. [36, 37] HBsAg provided the foundation for the development of screening and quality control strategies designed to improve the quality of 1.3 Detection of Viral Nucleic Acids plasma prior to the production of derivatives.
[27]
NAT offers a sensitive and flexible platform for the detection of The detection of HBsAg using specific monoclonal or viremia in both blood and plasma donors and creates additional polyclonal antibodies has a firmly established history in transfuopportunities to remove plasma units contaminated with clinically sion medicine and plasma industry practice. High levels of empty relevant pathogens, such as HBV, HCV, and HIV, and to defer virus particles, in addition to high titers of intact, infectious virus infected donors. With experience and further demonstration of particles, means that the detection of surface antigen is generally efficacy, NAT testing has the potential to supplant viral antigen an effective measure for the interdiction of donations from donors testing as a direct indicator of viremia, allowing for the elimination in the acute phase of infection. [28] Initial efforts to develop and of less effective, redundant tests. NAT testing is also emerging as implement screening tests involved multiple technology platan important technology for the detection of less severe viral forms. However, only a few could satisfy the operational requirepathogens, such as parvovirus B19 and hepatitis A virus (HAV). ments associated with the screening of whole blood and plasma
Infections with these pathogens are generally self-limiting because units. Assays that rely on solid-phase immunochemistry for the of an effective immune response. The use of NAT testing to detection of HBsAg, such as the RIA and ELISA, gained early identify only viremic donations for removal ensures that convalesfavor over more traditional assays that included complement fixacent donors whose plasma may contain protective, virus-specific tion and counterimmunodiffusion methods. [29] Currently, several antibodies are retained. NAT is also playing an increasingly imtest systems from different manufacturers are licensed by the US portant role in resolving issues particular to emerging pathogens FDA for use in donor screening and confirmatory testing. [12, 30] The for which the timely development and implementation of testing approval of more sensitive test systems is pending. [31] Although are critical. [3, 4, 38] the incidence of HBV infections varies significantly worldwide, representative studies of US volunteer blood donors indicate an
Trends in the Development of Nucleic Acid
infection rate of 1 per 63 000 donors.
[20]
Technology (NAT)
Nucleic acids have several properties that make them effective
Detection of HIV P24 Antigen
targets for detection. The ability of DNA and RNA to hybridize Drawing from the screening paradigm already established for with complementary molecules means that a great deal of control HBV, early emphasis was placed on the development of assays for can be exerted over assay specificity when target nucleic acid the direct detection of HIV-1. Public and political pressures sequences are known. NAT methods typically combine nucleic heightened the sense of urgency to close the infectious window acid hybridization with amplification technologies, driven either beyond what had been achieved through the implementation of enzymatically or chemically, to achieve highly sensitive detection anti-HIV antibody screening. [32] However, ambiguities surroundof specific nucleic acids. The PCR is the earliest and the most ing the outcome of several large clinical studies instilled a sense of widely recognized method that has been applied to the detection of uncertainty about the potential benefits associated with p24-anlimited quantities of viral nucleic acids. [39, 40] However, other tigen screening. [33, 34] Despite the doubts about the utility of methods offer alternative technology platforms with similar perp24-antigen testing in the field, the FDA adopted p24-antigen formance specifications for the amplification of nucleic acid screening as an interim measure to facilitate an expanded donor targets. These systems include transcription mediated amplifica-HIV screening protocol. [32, 35] However, other regional regulatory tion (TMA), [41] nucleic acid sequence based amplification (NASagencies, most notably those associated with Europe and Japan, BA), [42] thermophilic strand-displacement amplification declined to adopt this protocol. Because the safety benefit associ-(tSDA), [43] ligase chain reaction (LCR), [44] and branched DNA ated with the implementation of this expanded protocol has been assay (bDNA). [45] When coupled with efficient nucleic acid isolagenerally perceived as marginal, the replacement of the p24-antion methods, any of these technologies could provide a foundatigen test with more effective screening technology has been an tion for a highly efficient high-throughput testing platform.
NAT methods also provide opportunities to introduce economy peutics industry has applied NAT testing for HCV in pooled into a high-throughput testing environment. The increased sensiplasma samples to comply with European and US initiatives.
[55] tivity associated with NAT methods allows for the testing of NAT testing has also been implemented to improve the interdicpooled samples; individual samples need to be tested only when tion and removal of HIV-, HBV-, parvovirus-B19-, and HAVsuspected positive for a targeted pathogen. Because the vast macontaminated units from plasma inventories and manufacturing jority of samples are negative, pooling strategies greatly enhance streams. These NAT methods enhance the margin of safety of operational efficiency by reducing the number of test samples, blood and plasma products by allowing the detection of viral thus, effectively increasing throughput. The utilization of fluorespathogens earlier in the window period than can be achieved using cent or chemiluminescent detection chemistries with NAT methcurrent antigen and antibody tests. For example, the window ods facilitates process consolidation and reduces assay time. Addiperiod for HIV-1 associated with antibody assays is approximately tionally, probe-specific detection and target differentiation facili-22 days.
[14] The HIV-1 p24-antigen assay reduces the window tate the multiplexing of assays thereby increasing the array of period to 16 days. [56] The application of NAT assays for HIV-1 targets while reducing the number of tests performed. Finally, the RNA further reduces the window period to between 7 and 11 progressive introduction of automation will gradually reduce the days, [57, 58] depending on the pooling strategy employed. In the US, number of labor-intensive steps and further decrease the time the implementation of licensed HIV-1 NAT assays allows for a required to perform an assay. reduction in testing redundancies through the discontinuation of p24-antigen testing. However, in many developing countries, the Since 1995, an active dialog has been underway among scienimplementation of NAT techniques is hindered by its complexity tists from the blood and plasma industries, molecular diagnostic and high cost. developers, and regulatory agencies worldwide concerning the introduction of NAT methods into protocols established for testing
The implementation of new testing platforms and the upgrade blood-borne viral pathogens. Semi-annual meetings and internaof older ones are consistent with the strong emphasis on continutional collaborations have helped to establish standardized, unious improvement to which the biologic products industry has form policies. [46] The collaborative development of WHO internacommitted itself during the past decade. These testing procedures tional standards for NAT methods (table II) has provided the basis complement the viral removal and inactivation measures designed for various regional regulatory policies and industry initiatives.
into product-specific manufacturing streams to provide better safeThe application of the international unit, a description of empirity features for plasma-derived therapeutic proteins. cally derived, consensus-based potency, rather than a putative 2. Removal and Inactivation of Viruses physical entity, has enabled the creation of performance standards across multiple technology platforms. Legislation and guidance documents frequently specify performance standards for various
Viral Validation Studies
regions of the world.
By the early 1980s, the plasma industry had initiated viral
Applications of NAT
inactivation studies, [10] and in 1991, the EU Committee for PropriThe EU's codification of specifications for the detection of etary Medicinal Products (CPMP) required all manufacturers of pathogenic viral nucleic acids in pooled human plasma [54] opened blood and plasma products to implement viral inactivation/removthe door to a new era in the detection of viral pathogens in plasma al steps in their processes. In accordance with regulatory requireused in the manufacture of protein therapeutics. The plasma theraments, viral validation studies are performed to estimate the over- [47] Davis et al. [48] HBV HBV DNA 97/746 Saldanha et al. [49] HCV HCV RNA 96/790, 96/798 Saldanha et al., [50] Saldanha et al. [51] HAV HAV RNA 00/560 Saldanha et al. [52] Human parvovirus B19 Parvovirus B19 DNA 99/800 Saldanha et al. [53] HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus. all level of virus reduction across manufacturing processes. During regulatory authorities recommend incorporating at least two effecthese studies, known amounts of virus are deliberately added tive steps with unrelated clearance mechanisms in each manufac-(spiked) into production intermediates and the materials are treatturing process and at least one of the steps should be effective ed according to manufacturing specifications, using bench-scale against non-enveloped viruses.
[59] models of the production process. Virus reduction is calculated by Ideally, a pathogenic virus should be directly tested to detercomparing the level of virus infectivity remaining at the end of the mine the viral clearance values. However, not all clinically releprocess with the level in the starting material. Since most manuvant viruses can be propagated easily in vitro. As a result, specific facturing processes consist of multiple steps, challenging the sysmodel viruses with similar physicochemical characteristics are tem with virus at the beginning of a process and sampling the final used to represent the relevant but uncultivable viruses. In addition, product is not practical. Such a strategy would require massive non-specific model viruses with different physicochemical characamounts of virus, something that is difficult to obtain. As a result, teristics are included to evaluate the theoretical capability of the individual steps of a process are usually evaluated. Breaking down manufacturing process to clear unknown or undetected viruses. the process into individual steps is not only technically more Thus, no single indicator virus is used to assure the viral clearance reasonable, but it also allows for more accurate characterization of capacity of a manufacturing process for known and unknown the conditions critical for viral reduction and a better understandviruses. Instead, a test panel of relevant and model viruses is used ing of the mechanisms for viral clearance.
in validation studies to determine the capacity of viral reduction in manufacturing processes. Table III is a short list of common model Virus reduction is expressed on a logarithmic scale. The overall (test) viruses that are used in viral validation studies to mimic virus reduction capacity of a process is defined as the sum of the blood-borne viruses with potential for causing clinical infections. log reduction factors from individual steps. However, a simple summation of the individual reduction factors should not be used
Virus Removal Steps
as the only measure of viral safety. Individual clearance steps yielding <1 log10 are considered negligible and should not be included in the overall clearance for a process. Adding numerous Reduction in virus infectivity can be achieved through routine steps with low individual reduction factors or adding steps that processing and purification operations or by dedicated virus reducshare the same mechanism of virus clearance may overestimate tion steps. Depending on the method, clearance strategies can be the virus reduction capacity of a process. An effective step is one classified as removal (physical separation) or inactivation (irrethat clears at least 4 log10 units of virus (i.e. a 10 000-fold versible loss of viral infectivity). Virus removal is often achieved reduction in titer) and a robust step is one that clears virus by partitioning of viruses from the proteins of interest by precipitaregardless of variability in production parameters. In general, a tion, chromatography, or filtration. It should be emphasized that, single effective and robust step provides more assurance of viral to assure effective virus reduction by removal steps, processing safety than several steps with the same overall log reduction. Most conditions need to be carefully defined, controlled, and carried out in compliance with good manufacturing practices (GMP) regulaeffective against all viruses and that HCV was transmitted by tions.
immunoglobulins that were manufactured by a process that relied entirely on fractionation to remove virus. Consequently, additional
Cold Alcohol (Ethanol) Precipitation
viral inactivation/removal steps, with different mechanisms of Cohn-Oncley fractionation is a well established and efficient action, are required in manufacturing processes to assure viral method that allows for multiple stepwise extractions of therapeutic safety. [62] proteins (figure 1). Frozen plasma is thawed slowly at 35.6-39.2°F (2-4°C) and centrifuged to remove cryoprecipitate, the cold insol-
Caprylate (Octanoic Acid) Precipitation
uble plasma fraction that contains fibrinogen, Factor VIII (FVIII) Caprylate (octanoic acid) has been used to precipitate and and von Willebrand (vWB) factor. The solubility of different remove lipids/lipoproteins during the purification processes of protein fractions in the remaining supernatant (effluent) is then intravenous immunoglobulin (IVIG). [63] [64] [65] [66] Under acidic condimanipulated by adding different amounts of alcohol (ethanol) and tions, this treatment also inactivates/removes at least 4 log10 of changing the temperature, pH, and/or ionic strength conditions. enveloped viruses. [67] [68] [69] [70] When coupled with depth filtration, 2-4 After each alcohol precipitation, the fractions of different proteins log10 of non-enveloped viruses can also be removed. [67] [68] [69] [70] are separated (partitioned) by centrifugation or filtration.
Polyethylene Glycol Precipitation
Although not designed specifically for virus removal, some
Proteins are usually soluble in water solutions because their fractionation processes possess varying capacities for clearing hydrophilic amino acids interact with water molecules. Polyethylviruses. Viral validation studies help to explain how FVIII concenene glycol (PEG) is an inert, nondenaturing, water-soluble polytrates, produced before the implementation of viral inactivation mer that precipitates proteins (and viruses) from aqueous solutions measures, became contaminated with multiple viruses and why by excluding protein interactions with water. As an example, the immunoglobulins produced during the same period never trans-PEG precipitation step is capable of removing 3-4 log10 viruses mitted HIV. [60] The early FVIII concentrates were derived from during the α1-antitrypsin purification process.
[61] cryoprecipitate, and viral validation studies showed no viral clear-
Chromatography
ance across the initial precipitation step to generate cryoprecipitate. In contrast, immunoglobulins, which are derived from FracAlthough traditional purification schemes relied exclusively on tion II+III, undergo an additional precipitation step (Fraction III) alcohol precipitations, many newly developed processes for FVIII that not only purifies product but also removes >4 log10 of some and immune globulins use chromatography steps to remove conmodel non-enveloped and >3 log10 of some model enveloped taminants, including viruses. However, because of the complexity viruses. [61] It must be emphasized that fractionation steps are not of biologic process streams, chromatography is not typically used for primary extraction, but is more often employed as a downbiologic and immunologic reactions are not induced. [73] Nanofilstream polishing step of partially purified fractions. Chromatotration, in theory, is limited only by pore size, so the smaller the graphic methods separate proteins based on differences in their pore, the smaller the viruses that are retained. However, size-based physicochemical characteristics, and since viruses consist of many exclusion applies to plasma proteins as well as to viruses, and different proteins, they may be separated by many different kinds currently only the smallest plasma products pass easily through the of chromatographic methods.
filters. As nanofiltration technology improves, it is reasonable to expect the availability of membranes capable of separating viruses Affinity chromatography uses biologic ligands, such as antiboas small as parvovirus from proteins as large as IgG or FVIII. dies and co-factors, to recognize and bind their complementary proteins. [71] For example, during one purification process of FVIII, immobilized monoclonal antibodies specifically captured FVIII,
Viral Inactivation Methods
allowing contaminating proteins and 2.8 log10 porcine parvovirus Inactivation methods render viruses non-infectious by physical (PPV) and 3.7 log 10 poliovirus (both small non-enveloped viruses) or chemical means that, by themselves, may adversely affect the to pass through. [72] protein product. Examples of adverse effects include protein denaIon-exchange chromatography uses differences in charge to turation and loss of biologic activity, alteration of antigenicity, and separate proteins. Although the binding characteristics of proteins production of neoantigens and induction of antibodies or inhibitors during chromatographic processes are well understood, virus bindin the recipient. [74] Stabilizers are usually added to protect biologic ing is not. Consequently many of the ligands used for viral activity or to reduce protein aggregation. If the added stabilizers or clearance have relatively general binding properties and involve inactivating chemicals must be removed from the product, the combinations of ionic, hydrophobic, hydrogen bonding, or van der subsequent manufacturing steps to remove or reduce their levels Waals interactions. During one new IVIG purification process, the can result in recovery losses and extended processing times. The chromatography step not only separates impurities from IgG, but most commonly used chemical inactivation steps are treatment also clears >4 log10 bovine viral diarrhea virus (BVDV), a surrowith solvent/detergent and low pH. Acetone is used in some gate for HCV and PPV, a model for human parvovirus B19 and albumin processes and caprylate has been used to inactivate enremoves HIV, pseudorabies virus (PRV, model for human herpes veloped viruses in immune globulin solutions. Licensed methods viruses), Reovirus, and HAV to below detection. [70] to physically inactivate viruses also include pasteurization (heatDepth filters were originally developed for the plasma fractioning in solution),vapor heating, and terminal dry heat. ation industry to replace asbestos prefilters as clarifying filters and basically consist of diatomaceous earth, cellulose, and polymeric
Solvent/Detergent Treatment binding resins. Some binding resins also confer positive charges to
Solvent/detergent (SD) treatment, which disrupts the lipid coat the matrix, enabling the filters to function as an ion exchange of enveloped viruses, consists of gently stirring a plasma protein chromatographic medium. Depth filtration effectively removes solution in a non-volatile organic solvent, tri-n-butyl-phosphate enveloped and non-enveloped viruses from products such as IVIG, (TNBP) and detergent (Tween ® 1 80, Triton ® X-100, or sodium albumin, and α 1 -antitrypsin. [61] cholate). SD treatment was first licensed by the FDA in 1985 and
Nanofiltration
is considered a breakthrough in viral safety because of its simpliciUnlike chromatography steps that were developed for protein ty and effectiveness to inactivate enveloped viruses while mainpurification and where virus removal was coincidental, virus retaining high protein recovery. [75] HIV, BVDV, and PRV were tentive filters, or nanofilters, were developed specifically to reinactivated to below detection after SD treatment of FVIII and move viruses. Viruses larger than the pore size of the nanofilter are IVIG process intermediates. The downstream processes required retained by a combination of size exclusion and adsorption mechato remove the SD agents are often existing steps of removing nisms while the smaller less rigid plasma proteins pass through.
protein contaminants. The main limitation is its failure to inactiNanofiltration can be performed under relatively mild physiologic vate non-enveloped viruses. While there have been no HIV, HCV, conditions (pressure, pH, osmolarity, and temperature) and does or HBV transmissions by SD-treated plasma products since its not require stabilizers or other chemical agents. As a result, the introduction, there have been several cases of HAV and parvovirus biologic integrity of a product is not compromised and adverse B19 transmission from SD-treated clotting factor concentrates. [76] 1 The use of trade names is for product identification purposes only and does not imply endorsement.
Caprylate Inactivation
These results indicate that the model virus, PPV, is more resistant In addition to the capacity of inducing precipitation (section to heat treatment than parvovirus B19 and suggest the effective-2.2.2) caprylate can also inactivate viruses. The proposed mechaness of pasteurization to inactivate both enveloped and non-ennism for inactivation is that lipophilic non-ionized caprylate disveloped viruses in albumin. However, pasteurization in the presrupts viral lipid membranes and renders the virus non-infecence of sucrose was less effective against non-enveloped viruses, tious. [68] Caprylate inactivation studies for one new IVIG process as Reovirus reduction was only 1.0 log10. Similarly, a recent report showed that HIV, BVDV, and PRV were completely inactivated of parvovirus B19 transmission by a pasteurized immunoglobulin, after exposure for only 3 minutes. [70] Variations in incubation time, in the presence of stabilizers, indicates that heating in solution may temperature, pH, protein concentration, and caprylate concentranot be effective in eliminating high concentrations of non-ention within manufacturing specifications did not affect virus inacveloped viruses such as parvovirus B19. [81] tivation, demonstrating the potential of caprylate treatment for use
Vapor Heating
as a robust alternative to SD treatment. [77] Pressurized steam, or vapor heat, has been used to treat coagu-
Acetone
lation concentrates. Two-stage vapor heating, involving 10 hour, Although not very commonly used in manufacturing processes, 140°F (60°C), at 1190 mbar, followed by 1 hour, 176°F (80°C), at the washing of albumin paste with acetone has been shown to 1375 mbar, inactivated 10.9 log10 HIV, >12.4 log10 tickborne inactivate ≥5.1 log10 HIV, 4.5 log10 BVDV, and ≥4.2 log10 encephalitis virus, >11.5 log10 PRV, and >11.0 log10 equine PRV. [61] rhinopneumonitis virus (model for HAV). [82] While vapor heating inactivates enveloped viruses in general, [83] and some non-en-
Low pH Incubation
veloped viruses including HAV, [84] the treatment may not inactiSimilar to the fortuitous utility of alcohol precipitation as a vate parvovirus B19 completely. [85] virus removal step, low pH incubation serves two functions. Incubation of IVIG at low pH (pH 4.0-4.3) was initially developed
Terminal Dry Heat Treatment
to reduce anti-complementary activity, avoid aggregates, and perDuring terminal dry heat treatment, final containers of freeze mit intravenous infusion. However, incubation of IVIG at low pH dried product are heated at temperatures ranging from 140°F also inactivates substantial amounts of enveloped viruses. During (60°C) to 212°F (100°C) for varying lengths of time. [76] Terminal the low pH final incubation step of one IVIG purification process, dry heat treatments were developed to inactivate HIV in coagula-HIV, BVDV, and PRV were inactivated to below detection after tion factor concentrates and involved heating at 140-154.4°F 14, 21, and 4 days, respectively.
[61] (60-68°C).
[10] However, later studies showed that inactivation of other enveloped viruses, such as HBV and HCV, required more
Pasteurization (Heating in Solution)
stringent conditions. As a result, some FVIII products are treated Pasteurization, the heating of aqueous, stabilized protein soluby dry heat at even higher temperatures (e.g. 176°F [80°C]) for a tions, was developed during World War II when albumin was longer period of time (e.g. 72 hours). Such treatment inactivates shipped all over the world to treat cases of shock. [78] No cases of significant levels of both enveloped and non-enveloped viruses, HIV, HBV, or HCV have ever been traced to a transfusion of but the effectiveness of the step is dependent on residual cake pasteurized albumin. Pasteurization in the final container is the moisture [86] and formulation. [72] approved pharmacopeial method for viral inactivation in albumin preparations. [79] 
Viral Reduction Across Manufacturing Processes
The results of viral validation studies support the virucidal capacity of albumin pasteurization and extend its effectiveness to Experience with hepatitis viruses and HIV has led to the some non-enveloped viruses. Pasteurization of albumin final implementation of many viral removal and inactivation technolocontainer inactivated enveloped viruses, HIV, BVDV, PRV, and gies in the plasma fractionation industry. Currently, there is no non-enveloped viruses, Reovirus and HAV, to near or below 'magic bullet' to inactivate all viruses in all processes and such a detection.
[61] In contrast, only 1.6 log10 PPV reduction was technique is not anticipated in the near future. Thus, new producachieved after heating at 140°F (60°C) for 10 hours. Blumel et tion processes are designed to contain orthogonal reduction steps al. [80] confirmed the resistance of PPV during albumin pasteurizato assure broad and effective virus reduction within specific prodtion but also reported that parvovirus B19, unlike the model uct streams. Table IV summarizes viral reduction across several animal virus, was inactivated after heating for only 10 minutes.
representative manufacturing processes. The overall global reduc- a ≥ indicates that all the input virus was removed or inactivated to below detection and the calculated virus reduction across a step would have been greater if the virus spike had been higher. B19 = human parvovirus B19; BVDV = bovine viral diarrhoea virus; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; NA = not applicable; NT = not tested; PPV = porcine parvovirus; PRV = pseudorabies virus.
tion across each manufacturing process was calculated by adding significant reduction can be observed (table IV) . Non-enveloped all reduction factors from individual steps that were ≥1.0 log10. virus reduction is achieved by a combination of removal steps, These values are the collective results of the methods described in such as precipitation and filtration, nanofiltration, and inactivation the previous sections.
steps, such as pasteurization and dry heat treatment. For this group of viruses, which often leads to less severe clinical outcomes, EU For enveloped viruses, EU regulatory agencies now recomregulatory agencies require at least one effective (4 log10 or more) mend that manufacturing processes contain at least two effective reduction step. and mechanistically independent steps that have 4 log10 or more clearance capacity. These steps include chemical and physical
The presence of multiple steps that are capable of removing or treatment, precipitation, and filtration integrated to inactivate and inactivating a wide variety of viruses by completely different remove enveloped viruses. As shown in table IV, the capacity of mechanisms provides the greatest assurance that any virus survivmanufacturing processes to inactivate/remove enveloped viruses, ing one step will be cleared by another step. However, viral such as HIV, HCV, and HBV, is very high.
inactivation or removal steps are useful only if they are implemented properly in the production and carried out in adherence Clearance of non-enveloped viruses, such as parvovirus B19 and HAV, is more difficult across manufacturing processes. Still, with current GMPs (cGMPs). [87] Manufacturers of plasma prod-ucts have made major investments to improve elements critical for latency period, and small number of cases. [105] However, during product integrity and viral safety, such as facility and equipment 2004, two cases of presumptive vCJD transmission through the design, qualification and validation, process control and monitoruse of packed red blood cells were reported in the UK. [106, 107] ing, quality assurance, standard operating procedures, and staff Therefore, vCJD transmission by blood is possible, although very training. [88] Increasingly rigorous regulatory inspections during the rare. past decade also played a key role in promoting and enforcing There are no conclusive positive results from many early atcGMP compliance of the industry. [89] tempts to transfer CJD to animals through blood. [108] [109] [110] However, a relatively recent sheep model study has convincingly demon-3. Theoretical Risk of Prion Transmission strated the transmission of TSE by whole blood transfusion. Some of the blood samples were collected at pre-clinical stages, indicatPrion diseases, or transmissible spongiform encephalopathies ing that asymptomatic animals can carry the infectious (TSEs), are a group of fatal neurodegenerative disorders linked to agent. [99, 111, 112] By using intracerebral inoculations, infectivity has misfolded prion proteins. [90] [91] [92] [93] The most notable TSEs include also been detected in blood samples from rodent TSE modscrapie in sheep, bovine spongiform encephalopathy (BSE) or els. [113] [114] [115] [116] 'mad cow disease' in cattle, and Creutzfeldt-Jakob Disease (CJD) in humans. All these diseases feature a long latency period ranging
Testing for Creutzfeldt-Jakob Disease (CJD)
from years to decades and the accumulation of the pathogenic An obvious solution for the management of CJD-related risk is prion protein (scrapie form) [PrP Sc ] mainly in the CNS.
to implement a screening assay capable of detecting a marker for Following an epidemic of BSE in the UK in the 1980s, a new the illness at the pre-clinical stage. In the US alone, it is estimated form of CJD appeared mainly in the UK with distinctive clinical that ~5% of blood donors are deferred because of the theoretical and pathologic features, including the appearance of PrP Sc in risk of vCJD transmission.
[117] Since vCJD is virtually non-exislymphoid tissues that had not been described in classical CJD tent in the US, the donor loss could be avoided if an accurate cases. This new illness was named variant CJD, or vCJD, to screening test were available. distinguish it from other CJDs. Epidemiologic and experimental However, the pathogenic prion protein has so far evaded detecevidence strongly suggested a causal link between BSE and vCJD, tion in blood samples and no practical ante-mortem screening test possibly due to the consumption of BSE-contaminated meat prodfor this pathogen is currently available. [118] [119] [120] [121] [122] [123] [124] On the other hand, ucts. [94] [95] [96] the growing practice of using post-mortem tests to exclude infectThe emergence of vCJD, along with its possible oral route of ed beef from human consumption reduces the risk of transmitting transmission and peripheral lymphoid tissue involvement, [97, 98] BSE to human populations, thus indirectly improving the safety of prompted concerns that vCJD may pose a higher risk level than blood or blood products. classical CJD in terms of transmission through blood or blood
CJD-Related Donor Deferral Policies
products. Therefore it is important to examine such a risk based on
In the absence of a reliable ante-mortem, in vitro diagnostic test epidemiologic and experimental evidence.
for CJD, a deferral policy is the only way to exclude high-risk donors. Donors with a family history of CJD and patients who with the transmission of CJD (dura mater transplant or human pituitary-derived growth hormone administration) are excluded. A From an epidemiologic point of view, if classical CJD can be decision has also been made to stop processing UK plasma into transmitted through blood or blood products, a few cases over a derivatives. [125] long period of time would be expected among frequent blood or blood product recipients, such as patients with hemophilia, thalas-A major challenge is how to defer donors who have an elevated semia, or sickle cell disease. However, the rate of classical CJD risk of having been exposed to a BSE agent. After balancing the occurrence is not elevated in these populations. [99] [100] [101] [102] Retrospectheoretical risk of CJD transmission with the need for a stable tive studies have also been conducted on transfusion recipients blood supply, regulatory agencies around the world have recomfrom donors who later developed classical CJD. Again, no classimended geographical deferral policies. These policies mainly excal CJD transmission was detected. [103, 104] For vCJD, epidemioloclude donors who spent a certain amount of time in the UK during gy data remain limited because of the disease's short history, long the BSE epidemic period between the beginning of 1980 and the end of 1996. The US has the most stringent criteria, which exclude ty. [127, 128] The correlation between the clearance of PrP Res and donors who stayed in the UK for a cumulative 3 months, or in infectivity in plasma purification processes has been demonstratFrance for a cumulative 5 years, or on military bases in Europe for ed. [129] A prion confirmation-dependent immunoassay has also a cumulative 6 months during the risk period. The US policy also been developed and used for bench-scale clearance studies. [130] excludes donors who had blood transfusions or received bovine
Methods of Prion Removal
insulin prepared in the UK from 1980 to present. [117] Australia and Separation of prions from other protein entities may be accomJapan both defer donors who spent more than 6 months in the UK plished by exploiting the prions' structural and solution-state during 1980-1996. These policies are likely to be revised as the properties. Prions are hydrophobic aggregates of the β-sheet form mechanism of CJD transmission becomes better understood.
of the prion protein and are often associated with cellular components such as membranes. These aggregates vary in size from
Removal of Prions
nanometers to microns depending on the source and preparation of the tissue. If the desired therapeutic protein is small compared with
Prion Removal Versus Inactivation
the prion particles, sedimentation or filtration can be used to The prion agent is very robust, and treatments such as heat, remove the prion impurity. Use of well defined solution conditions solvent detergent, and ionizing radiation that inactivate viruses (pH, organic agents, and temperature) can promote the aggregacannot be relied upon to eliminate the TSE infectivity. TSE tion/precipitation of the prion, which can be removed using sediinactivation can be achieved using extreme methods, such as mentation or filtration (table V) . At this time, the degree of prion treatment with caustics and autoclaving, methods that will also clearance cannot be reliably predicted on the basis of the condidestroy the biologic product of interest. [126] Therefore, the removal tions used to purify proteins. Thus, it is a prudent practice to of the prion agent is the only viable means to reduce the theoretical evaluate the removal of the prion agent on a case-by-case basis, risk associated with the transmission of TSEs through plasmaand not rely on analogy. derived proteins.
Examples of Prion Removal

Bench-Scale Models for Prion Clearance Studies
One of the best studied processes for prion clearance is the To determine the capacity of prion removal for a manufacturing Cohn-Oncley fractionation. The general methodology of this proprocess, prion clearance studies are performed. These studies are cess (see section 2.2.1) is to lower the temperature of plasma, analogous to viral clearance studies where bench-scale models of increase the alcohol concentration, and make pH adjustments to manufacturing processes are used (section 2.1). The TSE spikes selectively precipitate classes of proteins. A number of laboratoare typically derived from infected brain homogenate because of ries have investigated the inherent ability of the Cohn-Oncley the high titers of the prion protein and infectivity (also see section process to remove spiked prion protein and infectivi-3.2.5).
ty. [114, 115, 127, [131] [132] [133] [134] Cryoseparation and Fraction I separation yield The partitioning of TSE infectivity during a purification proFactor VIII/vWB and Fibrinogen/Factor IX, respectively (figure cess can be monitored by rodent bioassay. Although sensitive, 1). These two plasma intermediates have the highest protein such an assay typically requires a number of months to complete.
concentrations, and the clearance of spiked prions is ≤1 log10. Alternatively, a sensitive Western Blot assay has been developed Following the Fraction I separation is the Fraction II+III separaand used to monitor the partitioning of the proteinase resistant tion, which is the first significant prion removal step. The effect of form of prion, or PrP Res , as a surrogate marker for TSE infectivi-20% (volume/volume) alcohol combined with low temperature and centrifugation results in ≥4.7 log10 of removal of PrP Sc with hamster 263K, which is a PrP Sc strain derived from sheep scrapie, respect to the effluent. [61] This suggests that prions can be precipiis used in clearance studies. However, it is important to establish tated or aggregated using specific solution-state conditions. The hamster scrapie as a valid model for the partitioning of human Fraction II+III clearance is clearly beneficial for the downstream prions. A comparative study of the partitioning of human, sheep, products (α1-antitrypsin, plasma protein fraction, and albumin) in and hamster forms of PrP Sc was conducted. [125] Three plasma the Cohn-Oncley process. However, this removal is not in favor of purification steps were chosen that demonstrated low (cryoseparathe immunoglobulin product, as the prion spike copurifies with the tion, about 1 log10), intermediate (3% PEG precipitation, 2-3 Fraction II+III paste, which is the starting material for the IVIG log10), and high (11.5% PEG precipitation, 3 log10) clearance of process. Fortunately, there are steps during immunoglobulin puriPrP Sc in the hamster scrapie spike model. In brief, it was found fication that significantly clear spiked prions from the immuthat PrP Sc derived from vCJD, classical CJD, sporadic CJD, or noglobulin product. For example, the Fraction III separation relies Gerstmann Sträussler Sheinker disease human brain tissue partion solution conditions that maintain the solubility of IgGs in 17% tioned quantitatively similarly to PrP Sc derived from sheep or alcohol at low temperatures while precipitating the prions, which hamster scrapie. [133] These data indicate that in the case of bioare removed (≈4 log10) using centrifugal sedimentation. chemical separations, hamster scrapie can be used to predict the partitioning of human and other species of prions. Factors that control the precipitation of PrP Sc during the Cohn-
The preparation of the spiking material is a related issue. [132, 134] Oncley fractionation have been investigated in some detail. [131] The physical properties of circulating TSE infectivity in blood Several factors were identified that controlled the precipitation of have not been measured. Brain homogenate may or may not be an PrP Sc in solution; among these were pH, alcohol content, and salt ideal model of endogenous circulating TSE infectivity. concentration. Other parameters such as total protein concentraMicrosomal and highly purified preparations from brain homogetion, specific protein constituents, and temperature were found to nate have been proposed and investigated as alternatives to the be less important in terms of precipitating PrP Sc . crude brain homogenate. As a rule, the membrane-bound forms of A new IVIG product has been developed using a chromatothe TSE infectivity and prion protein (i.e. crude, clarified, or graphic process as the major purification method. [65] In this promicrosomal fractions of brain homogenate) result in the lowest cess, prions are effectively precipitated at low pH in presence of removal measured in spiking studies. Highly purified forms, such caprylate and removed by a subsequent filtration step. A signifias fibrils or full length scrapie protein, tend to result in very high cant prion reduction factor of >4 log10 has been validated for this levels of removal. Thus the use of less purified fractions represents step in the process.
[61] Other organic agents, such as PEG, can also the most conservative estimation of prion removal. be used to effectively remove spiked prions from process intermediates. In one such purification process, the addition of 11.5% PEG 3350 yielded ≥4.9 log10 of PrP Sc removal. [61, 129] 4. Conclusion Utilizing precipitation coupled to sedimentation and filtration are not the only effective means to remove prions and reduce the During the past 2 decades, the overall risk of acquiring serious risk of TSE transmission. Nanofiltration, a size exclusion-based viral diseases through plasma-derived proteins has been reduced method, has also demonstrated a significant (≥4 log10) potential significantly. In fact, no confirmed transmission of HBV, HCV, or for the removal of prions. For example, the Viresolve ® NFP HIV by US licensed, virally reduced plasma derivatives has been (Normal Flow Parvovirus) and Viresolve ® 180 membranes (Millireported in recent years. [60] This favorable status is the result of a pore, Billerica, MA, USA) yield removal of various preparations combination of measures, including the screening and deferring of of prion spikes from model and process solutions. [61] Similar high-risk donors, the testing of collected donations using immuremoval values were measured using Novasip ™ DV20 (Pall Corp., noassays and NAT, the incorporation and validation of virus East Hills, NY, USA) and Planova ® 15N (Asahi Kasei Pharma, removal and inactivation steps in production processes, and the Tokyo, Japan) nanofilters. [135] Chromatography methods may also establishment of increasingly stringent pathogen safety regulabe effective in removing prions to various degrees. [132] tions.
In spite of these advances, the risk of pathogen transmission
Relevance of Spiking Material
from plasma products can never be assumed to be nonexistent. An issue related to the investigation of prion removal is the use Currently unknown viruses could emerge, known viruses could of spiking material derived from rodent brain tissue. Typically, redistribute geographically or mutate into new strains. The devel- To this end, manufacturers of plasma-derived biologic products 
